David L. Mahoney's most recent trade in Corcept Therapeutics Inc was a trade of 30,000 Common Stock done at an average price of $5.9 . Disclosure was reported to the exchange on March 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.86 per share. | 13 Mar 2026 | 30,000 | 30,000 (0%) | 0% | 5.9 | 175,800 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2026 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Other type of transaction at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 1,237,145 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 0 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.15 per share. | 13 Mar 2026 | 5,469 | 24,531 (0%) | 0% | 32.1 | 175,828 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 15,000 | 15,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 30,000 | 0 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 16 May 2025 | 30,000 | 30,000 (0%) | 0% | 6.6 | 196,500 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 74.17 per share. | 16 May 2025 | 23,829 | 3,523 (0%) | 0% | 74.2 | 1,767,452 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 74.65 per share. | 16 May 2025 | 3,523 | 0 (0%) | 0% | 74.7 | 263,001 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.21 per share. | 16 May 2025 | 2,648 | 27,352 (0%) | 0% | 74.2 | 196,508 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 30,000 | 30,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.74 per share. | 10 Apr 2024 | 30,000 | 30,000 (0%) | 0% | 1.7 | 52,200 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 30,000 | 0 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Other type of transaction at price $ 0.00 per share. | 10 Apr 2024 | 27,806 | 1,212,614 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Other type of transaction at price $ 0.00 per share. | 10 Apr 2024 | 27,806 | 27,806 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.80 per share. | 10 Apr 2024 | 2,194 | 27,806 (0%) | 0% | 23.8 | 52,217 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Aug 2023 | 34,850 | 1,169,808 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Aug 2023 | 34,850 | 46,147 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Aug 2023 | 17,420 | 1,204,658 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 30.95 per share. | 14 Aug 2023 | 15,000 | 1,222,078 (1%) | 0% | 30.9 | 464,201 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 30.95 per share. | 14 Aug 2023 | 10,000 | 11,297 (0%) | 0% | 30.9 | 309,467 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 30,000 | 30,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.74 per share. | 08 May 2023 | 30,000 | 1,239,275 (1%) | 0% | 1.7 | 52,200 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2023 | 30,000 | 0 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.76 per share. | 08 May 2023 | 2,197 | 1,237,078 (1%) | 0% | 23.8 | 52,201 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,030 | 1,230,572 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 21,297 | 1,209,275 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 20,000 | 20,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2022 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.05 per share. | 27 May 2022 | 30,000 | 30,000 (0%) | 0% | 4.1 | 121,500 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.00 per share. | 27 May 2022 | 5,786 | 24,214 (0%) | 0% | 21 | 121,506 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.42 per share. | 11 May 2021 | 30,000 | 118,984 (0%) | 0% | 4.4 | 132,600 | Common Stock |
| Corcept Therapeutics Inc | David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.45 per share. | 11 May 2021 | 6,484 | 112,500 (0%) | 0% | 20.5 | 132,598 | Common Stock |